Last reviewed · How we verify
Sancuso patch
Sancuso is a granisetron transdermal patch that blocks serotonin 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
Sancuso is a granisetron transdermal patch that blocks serotonin 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Prevention of nausea and vomiting associated with emetogenic chemotherapy, Prevention of postoperative nausea and vomiting (PONV).
At a glance
| Generic name | Sancuso patch |
|---|---|
| Sponsor | LG Life Sciences |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Granisetron is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced nausea and vomiting (CINV) by blocking serotonin signaling at peripheral and central sites. The transdermal patch formulation provides sustained drug delivery over several days, maintaining therapeutic levels without repeated dosing. This approach is particularly useful for patients undergoing highly emetogenic chemotherapy regimens.
Approved indications
- Prevention of nausea and vomiting associated with emetogenic chemotherapy
- Prevention of postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Constipation
- Application site reactions
- Asthenia/fatigue
- Diarrhea
Key clinical trials
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years (PHASE1)
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (PHASE1)
- An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron (PHASE1)
- Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects (PHASE1)
- Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS) (PHASE1)
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years (PHASE1)
- PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |